Publication: Kistik fibrozisli hastalarda akut alevlenme sırasında başlanılan bottle-pep tedavisinin sürdürülebilirlik ve güvenilirliğinin araştırılması
Abstract
Amaç: Bu çalışmada akut alevlenme sırasında görülen Kistik fibrozis(KF)’li hastalarafizyoterapist gözetiminde verilen bottle-pep eğitimi sonrası ev olarakuygulanan rehabilitasyon sürecinin sürdürebilirlik ve güvenilirliğinindeğerlendirilmesi ve bu popülasyondaki farklı sekresyon temizleme yöntemlerikullanan hastalarla karşılaştırılması amaçlanmıştır.Gereç ve Yöntem: Çalışmaya akut alevlenme dönemindeki 6-18 yaş arası KF tanılıhastalar alındı. Bu hastalardan herhangi bir yöntem kullanmayanlara yetkin birfizyoterapist tarafından Bottle-PEP eğitimi verildi, halihazırda başka bir cihazkullananlar mevcut cihazlarıyla takibe alındı. Böylece iki gruba ayrılan hastalar 1 yılsüreyle takip edildi. Hastalar takipleri boyunca 2 haftada bir alevlenme gelişimi,cihazın düzenli ve uygun kullanımı ve memnuniyet açısından telefonla değerlendirildi.Hastalar her 3 ayda bir solunum fonksiyon testleri, 6 dakika yürüme testi(6DYT) veKF Anketiyle değerlendirildi.Bulgular: Çalışmaya 34 hasta dahil edildi. Her iki grup arasında cinsiyet, BMİ,başlangıç FEV1 ve 6 DYT değerleri açısından anlamlı fark bulunmamaktaydı.Takipler sırasında hastaların akut alevlenme skoru Bottle-PEP grubunda 4.5 (min 0maksimum 21) iken diğer grupta 6 idi (min 4 maksimum 13) ve her iki grup arasındaanlamlı bir farklılık yoktu (p=0.1). Her iki grupta da memnuniyet skorları 27 üzerinden27 idi (p=1). Tedaviye uyum skorları karşılaştırıldığında Bottle-PEP grubu ortancadeğeri 24 (min 2 maksimum 27), diğer grubun ortanca değeri 27 idi (min 4 maks 27)ve her iki grup arasında anlamlı farklılık yoktu (p=0.6). Hastaların 3 aylık kontrolleri sırasındaki FEV1, 6 dakika yürüme testi ve yaşam kalitesi verileri açısından anlamlıfarklılık saptanmadı (p>0.05).Sonuç: Bottle-PEP tedavisi kistik fibrozis tanılı hastalarda uzun dönemkullanılabilirliği ve güvenliği açısından diğer cihazlardan farklı değildir.
Objective: we aimed to evaluate the sustainability and reliability of the bottle-pep inpatients olmwith Cystic fibrosis (CF) and to compare it with patients using differentmethods.Materials and Methods: Patients with CF at the age of 6-18 years in acuteexacerbation period were included in the study. Bottle-PEP training was given by acompetent physiotherapist to those patients who did not use any method, and thosewho currently use another device were followed up with their existing devices. Thus,patients divided into two groups were followed up for 1 year. The patients wereevaluated by phone every 2 weeks for exacerbation, regular and proper use of thedevice, and satisfaction during their follow-up. The patients were evaluated every 3months with pulmonary function tests, 6-minute walking test (6MWT) and CFQuestionnaire.Results: 34 patients were included in the study. The acute exacerbation score of thepatients was 4.5(min0, max21) in the Bottle-PEP group and 6(min4 max13) in theother group, there was no significant difference between the two groups(p=0.1).Treatment compliance scores were compared, the median value of the Bottle-PEPgroup was 24 (min2 max27), the other group was 27 (min4 max27), and there was nosignificant difference(p=0.6). During follow-up of, there was no significant differencein FEV1, 6-minute walk test and quality of life data (p>0.05).Conclusion: Bottle-PEP treatment is not different from other devices in terms of longterm usability and safety in patients diagnosed with cystic fibrosis.
Objective: we aimed to evaluate the sustainability and reliability of the bottle-pep inpatients olmwith Cystic fibrosis (CF) and to compare it with patients using differentmethods.Materials and Methods: Patients with CF at the age of 6-18 years in acuteexacerbation period were included in the study. Bottle-PEP training was given by acompetent physiotherapist to those patients who did not use any method, and thosewho currently use another device were followed up with their existing devices. Thus,patients divided into two groups were followed up for 1 year. The patients wereevaluated by phone every 2 weeks for exacerbation, regular and proper use of thedevice, and satisfaction during their follow-up. The patients were evaluated every 3months with pulmonary function tests, 6-minute walking test (6MWT) and CFQuestionnaire.Results: 34 patients were included in the study. The acute exacerbation score of thepatients was 4.5(min0, max21) in the Bottle-PEP group and 6(min4 max13) in theother group, there was no significant difference between the two groups(p=0.1).Treatment compliance scores were compared, the median value of the Bottle-PEPgroup was 24 (min2 max27), the other group was 27 (min4 max27), and there was nosignificant difference(p=0.6). During follow-up of, there was no significant differencein FEV1, 6-minute walk test and quality of life data (p>0.05).Conclusion: Bottle-PEP treatment is not different from other devices in terms of longterm usability and safety in patients diagnosed with cystic fibrosis.
